Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are the standard of care for resectable and metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations (EGFRm). We describe the real-world practice of EGFRm testing, prevalence, treatment and outcomes in EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Abdul Rahman, Onal, Huseyin Cem, Tan, Daniel Shao-Weng, Soo, Ross A., Prabhash, Kumar, Kumar, Amit, Huggenberger, Reto, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478745/
https://www.ncbi.nlm.nih.gov/pubmed/36119641
http://dx.doi.org/10.1177/17588359221122720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478745/
https://www.ncbi.nlm.nih.gov/pubmed/36119641
http://dx.doi.org/10.1177/17588359221122720

Ejemplares similares